What is the main business of Orthoskan?

The main business activity of Orthoskan focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on November 24, 2022.

Where is the headquarters located?

The headquarters is located at: ul. Muchoborska 18, 54-424 Wrocław.

Who is on the management board?

The management board consists of: Paweł Krowicki (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 10,000 (approx. $2,701).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

The company reported a revenue of $15,263 in 2025, which is a decrease of 64.2% compared to 2024.

No, in 2025 the company was not profitable, reporting a net loss of $508,908.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $982 in 2025, representing 100% of all operating expenses.

Orthoskansp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2022-11-24

Share capital

10,000.00 PLN

Registered address

ul. Muchoborska 18, 54-424 Wrocław, Poland

Financials

Revenue history (in k)

Filing timeliness

1 of 3 financial statements was filed late (for 2025, 1 day late).

202516/07/2026
202425/06/2025
202308/07/2024

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 15.26kMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD -508.91kMedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 981.67MedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 431.44MedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Paweł Krowicki – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
ASI Igs Investment sp. z o.o. + limited partnership	50	$675.31	25%
Piotr Stanisław Kowalewskiage 47	51	$688.82	25.5%
Paweł Krowickiage 47	51	$688.82	25.5%
Orthoget sp. z o.o.	48	$648.30	24%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2023-01-21.

mBank
92 1140 2004 0000 3202 8311 2897

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Nov 20, 2023	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$2,403$2,403	Prezes Polskiej Agencji Rozwoju Przedsiębiorczości
Dec 9, 2022	Aid for SME access to finance — aid for start-ups	$179.5K$179,453	Dyrektor Narodowego Centrum Badań i Rozwoju

Competitors

Name	Revenue	Website
Vitrotest Europesp. z o.o.	$233,350.77	vitrotest.pl
VASA Therapeuticssp. z o.o.	$216,535.01	vasatherapeutics.com
MultiqureS.A.	$149,394.35	purebiologics.com
GenomtecS.A.	$54,746.36	genomtec.com
InventroS.A.	$12,176.61	inventro.co
Detoxedsp. z o.o.	$11,972.37	detoxed.pl
ArthecS.A.	$10,911.16	arthec.eu
Vitagenumsp. z o.o.	$9,376.94	vitagenum.pl
Centrum Transferu Technologii Meditransfer Iitdsp. z o.o.	$228.56	iitd.pan.wroc.pl
Olenasp. z o.o.	–	imsolutions.pl